[2H9]-Valsartan;rac-Valsartan D9;Cefuroxime Impurity 73;[2H9]-Valsartan (mixture);ACWBQPMHZXGDFX-KDDXQTGLSA-N;VALSARTAN-D9 (D7-D9 MIXTURE);L-Valine, N-(1-oxopentyl-d9)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-;(2S)-3-methyl-2-[2,2,3,3,4,4,5,5,5-nonadeuteriopentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;Valsartan D9Q: What is
Valsartan D9 Q: What is the CAS Number of
Valsartan D9 Q: What is the storage condition of
Valsartan D9 Q: What are the applications of
Valsartan D9
An isotopically labelled version of Valsartan (V095750), a nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive.
생물학적 활성
Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM). It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro. In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes. Formulations containing valsartan have been used in the treatment of hypertension and heart failure.
